Australia markets close in 4 hours 8 minutes

Paradigm Biopharmaceuticals Limited (PAR.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
1.4150+0.0250 (+1.80%)
As of 11:42AM AEDT. Market open.
Full screen
Previous close1.3900
Open1.4000
Bid1.4100 x 250400
Ask1.4200 x 1420100
Day's range1.3800 - 1.4300
52-week range0.8550 - 2.1543
Volume106,314
Avg. volume496,889
Market cap399.365M
Beta (5Y monthly)1.20
PE ratio (TTM)N/A
EPS (TTM)-0.1980
Earnings date22 Feb 2023 - 27 Feb 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.20
  • PR Newswire

    Paradigm Achieves Primary Endpoint in PARA_OA_008 Synovial Fluid Biomarker Phase 2 Clinical Trial

    Paradigm Biopharmaceuticals Ltd (ASX: PAR) (Paradigm or the Company), a late- stage drug development company focused on delivering new therapies to address unmet medical needs, is pleased to announce that the primary endpoint has been met and additionally significant improvement in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and function scores were demonstrated for injectable iPPS in the PARA_OA_008 phase 2 clinical trial.

  • PR Newswire

    MPS Clinical Program Update and Paradigm to Present at the International Conference on Lysosomal Diseases

    Paradigm Biopharmaceuticals Ltd (ASX: PAR) ("Paradigm" or "the Company"), a late-stage drug development company, is pleased to announce that it is scheduled to present data from the open-label phase 2 study of pentosan polysulfate sodium (PPS) for mucopolysaccharidosis type I (MPS-I) as an oral presentation at the 2023 ICLD meeting. Paradigm is also pleased to provide an update on the ongoing multi-centre double-blind randomised phase 2 study comparing PPS to placebo in mucopolysaccharidosis typ

  • PR Newswire

    Paradigm Partners with NFL Alumni Health on Osteoarthritis Program

    Paradigm Biopharmaceuticals Ltd (ASX: PAR) (Paradigm or the Company) a clinical stage biopharmaceutical company focussed on repurposing existing molecules for new indications with unmet clinical needs, is pleased to announce it has entered into a corporate partnership with NFL Alumni Health (NFLAH). This partnership will inform NFL Alumni Association (NFLAA) members about osteoarthritis disease onset and progression, current treatment options, and provide information about actively enrolling cli